AR089203A1 - Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina y metodo de tratamiento - Google Patents
Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina y metodo de tratamientoInfo
- Publication number
- AR089203A1 AR089203A1 ARP120104675A ARP120104675A AR089203A1 AR 089203 A1 AR089203 A1 AR 089203A1 AR P120104675 A ARP120104675 A AR P120104675A AR P120104675 A ARP120104675 A AR P120104675A AR 089203 A1 AR089203 A1 AR 089203A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical formulation
- amythriptiline
- oximetazoline
- ketoprophen
- treatment method
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica líquida caracterizada porque comprende ketoprofeno entre 550 mM y 1 M, amitriptilina entre 55 mM y 1 M, oximetazolina entre 350 mM y 1 M, 1 - 100% (v/v) de un poliol y citrato de Na 10 - 500 mM, que tiene un pH de 4,5 - 7,0, donde el ketoprofeno, la amitriptilina y la oximetazolina son solubles, y donde el ketoprofeno, la amitriptilina y la oximetazolina son estables durante al menos seis meses cuando se los almacena a una temperatura de entre 2ºC y 30ºC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161515234P | 2011-08-04 | 2011-08-04 | |
US13/566,090 US20130035362A1 (en) | 2011-08-04 | 2012-08-03 | Stable Anti-inflammatory Solutions for Injection |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089203A1 true AR089203A1 (es) | 2014-08-06 |
Family
ID=47627326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104675A AR089203A1 (es) | 2011-08-04 | 2012-12-12 | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina y metodo de tratamiento |
Country Status (21)
Country | Link |
---|---|
US (3) | US20130035362A1 (es) |
EP (1) | EP2739266B1 (es) |
JP (2) | JP6174579B2 (es) |
KR (1) | KR101951064B1 (es) |
CN (1) | CN103957886B (es) |
AR (1) | AR089203A1 (es) |
AU (1) | AU2012289968B2 (es) |
BR (1) | BR112014002631B1 (es) |
CA (1) | CA2844152C (es) |
CL (1) | CL2014000267A1 (es) |
DK (1) | DK2739266T3 (es) |
ES (1) | ES2600153T3 (es) |
HK (1) | HK1198911A1 (es) |
IL (1) | IL230779B (es) |
MX (1) | MX347373B (es) |
NZ (1) | NZ621484A (es) |
PL (1) | PL2739266T3 (es) |
PT (1) | PT2739266T (es) |
RU (1) | RU2635521C2 (es) |
WO (1) | WO2013020021A1 (es) |
ZA (1) | ZA201401344B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015022095B1 (pt) | 2013-03-15 | 2021-12-07 | Tonix Pharmaceuticals, Inc | Composição farmacêutica, métodos de fabricação, composição eutética e uso de composições |
WO2016014408A1 (en) * | 2014-07-21 | 2016-01-28 | Board Of Regents, The University Of Texas System | Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same |
TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
US20170049134A1 (en) * | 2015-08-18 | 2017-02-23 | Empire Technology Development Llc | Meat tendering using food grade natural products for reducing muscle contraction |
JP7023690B2 (ja) | 2017-12-06 | 2022-02-22 | 株式会社東芝 | 道路維持管理システム、道路維持管理方法及びコンピュータプログラム |
WO2020188457A1 (en) * | 2019-03-15 | 2020-09-24 | Ftf Pharma Private Limited | Solutions for oral dosage |
JP7008887B2 (ja) | 2019-11-01 | 2022-01-25 | 三菱電機株式会社 | 劣化状態判定装置、劣化状態検査システム、及び、劣化状態検査方法 |
FR3123563A1 (fr) * | 2021-06-03 | 2022-12-09 | Algotherapeutix | Utilisation de l’amitriptyline et/ou l’un de ses sels pharmaceutiquement acceptable comme agent conservateur |
CN116165306B (zh) * | 2023-04-25 | 2023-11-17 | 湖南九典制药股份有限公司 | 酮洛芬凝胶贴膏中有关物质的分析测定方法及应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
IT1269583B (it) * | 1994-04-26 | 1997-04-08 | Bayer Italia Spa | Preparazioni farmaceutiche a base di una soluzione di ketoprofene in capsule di gelatina molle e metodo per la loro produzione |
KR100517210B1 (ko) * | 1994-12-12 | 2006-06-07 | 오메로스 코포레이션 | 통증,염증및경련억제용관주용액 |
RU2180852C2 (ru) * | 1994-12-12 | 2002-03-27 | Омерос Медикл Системс, Инк. | Ингибирующий раствор и способ подавления боли, воспаления или спазма |
US7091181B2 (en) * | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
IT1277741B1 (it) * | 1995-12-28 | 1997-11-12 | Dompe Spa | Composizioni farmaceutiche parenterali contenenti sali di alchilammonio di acidi 2-arilpropionici |
US7973068B2 (en) * | 1998-10-20 | 2011-07-05 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
US7022740B2 (en) * | 2004-04-29 | 2006-04-04 | Leonard Mackles | Lubricious ophthalmic solutions |
US20070053868A1 (en) * | 2005-03-08 | 2007-03-08 | Banner Pharmacaps, Inc. | Solvent system for enhancing the solubility of pharmaceutical agents |
CA2608486C (en) * | 2005-05-20 | 2011-08-23 | Omeros Corporation | Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures |
MX2008011236A (es) * | 2006-03-01 | 2009-02-10 | Tristrata Inc | Composicion y metodo para tratamiento topico de trastornos dermatologicos que responden a alquitran. |
WO2008098019A2 (en) * | 2007-02-05 | 2008-08-14 | Carbylan Biosurgery, Inc. | Polymer formulations for delivery of bioactive agents |
WO2008115572A1 (en) * | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
CA2827373C (en) * | 2011-02-15 | 2019-05-14 | Stuart D. Shanler | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
-
2012
- 2012-08-03 NZ NZ621484A patent/NZ621484A/en unknown
- 2012-08-03 KR KR1020147005619A patent/KR101951064B1/ko active IP Right Grant
- 2012-08-03 ES ES12819309.1T patent/ES2600153T3/es active Active
- 2012-08-03 CN CN201280049056.5A patent/CN103957886B/zh active Active
- 2012-08-03 DK DK12819309.1T patent/DK2739266T3/en active
- 2012-08-03 US US13/566,090 patent/US20130035362A1/en not_active Abandoned
- 2012-08-03 CA CA2844152A patent/CA2844152C/en active Active
- 2012-08-03 MX MX2014001368A patent/MX347373B/es active IP Right Grant
- 2012-08-03 PL PL12819309T patent/PL2739266T3/pl unknown
- 2012-08-03 PT PT128193091T patent/PT2739266T/pt unknown
- 2012-08-03 AU AU2012289968A patent/AU2012289968B2/en active Active
- 2012-08-03 EP EP12819309.1A patent/EP2739266B1/en active Active
- 2012-08-03 RU RU2014108159A patent/RU2635521C2/ru active
- 2012-08-03 WO PCT/US2012/049463 patent/WO2013020021A1/en active Application Filing
- 2012-08-03 JP JP2014524099A patent/JP6174579B2/ja active Active
- 2012-08-03 BR BR112014002631-9A patent/BR112014002631B1/pt active IP Right Grant
- 2012-12-12 AR ARP120104675A patent/AR089203A1/es not_active Application Discontinuation
-
2014
- 2014-02-02 IL IL230779A patent/IL230779B/en active IP Right Grant
- 2014-02-03 CL CL2014000267A patent/CL2014000267A1/es unknown
- 2014-02-21 ZA ZA2014/01344A patent/ZA201401344B/en unknown
- 2014-12-09 HK HK14112364.7A patent/HK1198911A1/zh unknown
-
2015
- 2015-12-16 US US14/971,154 patent/US20160166696A1/en not_active Abandoned
-
2016
- 2016-10-20 JP JP2016206234A patent/JP2017014288A/ja active Pending
-
2018
- 2018-01-31 US US15/885,462 patent/US20180344855A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089203A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina y metodo de tratamiento | |
CY1124024T1 (el) | Νεες ctla4-ig ανοσοπροσκολλητινες | |
CY1123407T1 (el) | Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης | |
CY1117419T1 (el) | Εναιωρημα βλαστοκυτταρου | |
AR096975A1 (es) | Formulación líquida en aerosol de un artículo electrónico para fumar | |
BR112013021136A2 (pt) | sistema e método para controle sincronizado de uma ceifeira e veículo de transporte | |
BR112014018402A8 (pt) | Aparelho, sistemas e métodos de barra de ferramentas agrícola | |
FR2985023B1 (fr) | Systeme de reconstruction de proprietes optiques d'un milieu diffusant, comprenant une source de rayonnement pulsee et au moins deux detecteurs de deux types differents, et procede de reconstruction associe | |
BR112012015721A2 (pt) | modificação covalente de proteínas dirigida por ligante | |
AR067309A1 (es) | Formulaciones farmaceuticas que contienen derivados de acido lipoico | |
AR081677A1 (es) | Metodos y composiciones para la administracion intratecal de iduronato-2-sulfatasa, recipiente, sistema para administracion intratecal | |
BR112015023417A2 (pt) | compostos heterocíclicos e seus usos | |
AR098168A1 (es) | Formulación estable de insulina glulisina | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
CL2014001100A1 (es) | Formulacion enzimatica liquida que comprende por lo menos una enzima para el entrecruzamiento y/o modificacion de proteinas lacteas en suspension de poliol-agua que contiene desde 25 a 100% (p/p) de poliol y que tiene un valor de ph dentro de la escala de 4,4 a 5,1; y metodo para preparar la formulacion. | |
CO7091174A2 (es) | Compuestos triazolo como inhibidores de pde10 | |
AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
UY34491A (es) | La composición herbicida que contiene ácido de 4-amino-3-cloro-6- (4-cloro-2-flúor-3-metoxifenil) pyridina-2-carboxílico o los derivados de los mismos y fluroxipir o los derivados de los mismos | |
CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
CL2015000363A1 (es) | Una formulacion de una capsula farmaceutica compuesta que comprende 1) una unidad independiente comprendiendo irbesartan o una de sus sales y 2) una unidad independiente comprendiendo un inhibidor de la hmg-coa reductasa o una de sus sales y un aditivo alcalino, en donde dichas unidades independientes se separan unas de otras dentro de la capsula; y su metodo de preparacion. | |
UY34552A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen | |
UY34796A (es) | Formulacion de tobramicina | |
AR088398A1 (es) | Preparacion de liberacion sostenida | |
ES2604837T3 (es) | Formulación de liberación sostenida que contiene anticuerpos para administración ocular | |
BR112017006001A2 (pt) | método, produtos, e produto com capacidade de venda, troca, comercialização |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |